Tromsø, Norway, 22[nd] December 2021 - ArcticZymes Technologies ASA (OSE: AZT)
announces the launch of new products and opening of the new production facility

ArcticZymes technologies launches the following products:

  · ArcticZymes R2D[TM] Ligase - Patent pending ligase with novel specificity
enabling the ligation of DNA to both ends of RNA using a DNA splint. The enzyme
is an enabling tool for new technology development and is expected to have broad
applicability in Molecular Diagnostics (MDx), Next Generation Sequencing (NGS),
and gene/RNA synthesis applications for potential therapeutic applications.

  · IsoPol[®] BST[+] High Concentration Glycerol FREE - highly concentrated
formulation of the DNA polymerase to support ongoing customer opportunities for
utility in new NGS platform technologies and Point-of-Care diagnostic test
developments.

  · M-SAN HQ ELISA kit - The new ELISA immunoassay product is an essential
support product for customers using the M-SAN HQ enzyme in biomanufacturing
processes for gene therapy and viral vaccine production. In combination with the
M-SAN HQ enzyme, the new immunoassay product provides a complete solution for
the critical elimination of DNA contamination during biomanufacturing.

  · M-SAN HQ enzyme (Upscaled) - The upscaling of M-SAN HQ enzyme was timed to
coincide with the launch of the new ELISA kit. The M-SAN HQ enzyme manufacturing
process has been upscaled and transitioned to large-scale fermentation. This
successful upscaling achieved greater than a 100-fold increase in fermentation
yield. The upscaling was necessary to meet the expected increase in demand
following the launch of the ELISA kit and ensure customers can receive large
quantities of enzyme from a single production batch.

The ArcticZymes R2D[TM] Ligase and M-SAN HQ products will be available in our
warehouses during January 2022. The IsoPol[®] BST[+] High Concentration Glycerol
FREE product will be available during February 2022.

Furthermore, ArcticZymes Technologies is proud to announce the opening of its
new 500 m[2] production facility at the SIVA Innovation Centre in Tromsø. The
new state of the art facility caters for the scalable manufacturing of enzyme
products and meets the strict requirements demanded by ISO13485: In Vitro
Diagnostics (IVD) and cGMP. The facility has the capacity to support the
increasing production demands of existing products, future innovations, and
organic growth of the business over the next 4-5 years. Lastly all Tromsø based
employees are now located under one roof at the SIVA Innovation Centre.

ArcticZymes Technologies ASA, CEO, Jethro Holter said:

"It is a proud day for ArcticZymes Technologies and its employees to bring new
innovations to its customers.

We are delighted with the new production facilitates and inspired by the
prospect they will be instrumental in supporting future organic growth."

For more information, please contact:

ArcticZymes Technologies
CEO, Jethro Holter        Tel: +47 46 85 91 46
CFO, Børge Sørvoll        Tel: +47 95 29 01 87
                            ir@arcticzymes.com

About ArcticZymes Technologies ASA

ArcticZymes Technologies is a Norwegian life sciences company focused on the
development, manufacturing and commercialization of novel recombinant enzymes
for use in molecular research, In Vitro Diagnostics (IVD) and therapeutics.

Listed on the Oslo Stock Exchange since 2005 originally under the [Biotec]
ticker, as Biotec Pharmacon. The company rebranded as ArcticZymes Technologies
in 2020 under the [AZT] ticker. Its headquarters are based in Tromsø, Norway, at
the SIVA Innovation Centre.

ArcticZymes Technologies' IP and capabilities are protected via a large
portfolio of patents.

For more information, please visit the website: www.arcticzymes.com.